23 Feb Bone Therapeutics
Miguel Forte, M.D., Ph.D., CEO
April 20 | 11:15am | Gaudi 3 Ballroom
Bone Therapeutics is a listed, clinical-stage, cell therapy company committed to rebuilding the lives of patients suffering from debilitating bone conditions. Leveraging its extensive expertise in mesenchymal stromal cells, bone physiology, and patented manufacturing technology, Bone Therapeutics is developing a commercially ready, allogeneic, and off-the-shelf bone cell therapy platform, ALLOB, designed to offer patients and physicians best-in-class treatment options. In Phase II clinical development, ALLOB targets large orthopaedic conditions with high unmet needs, such as unhealed fractures and spinal fusion. To address a broader array of underserved clinical indications, Bone Therapeutics is building a next generation of cell therapy platform, based on iPSC derived MSCs. These highly standardized and scalable cells can be readily adapted by gene editing and cellular programming. This novel iMSC platform will be Bone Therapeutics’ next stepping stone to develop tailored cell and gene therapy products that have strong anti-inflammatory and immunomodulatory properties to treat acute life-threatening diseases.